Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Lenvatinib in second-line advanced ESCC
NCT06746961Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Dose Limiting Toxicities, Recommended Phase 2 Dose and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06746961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746961.